Prophylactic Antibiotics in Bronchiectasis: Why, How, and What You Should Know

What are prophylactic antibiotics in bronchiectasis?

Prophylactic antibiotics in bronchiectasis are long-term antibiotics used to reduce flare-ups, also called exacerbations. They are not the same as a short rescue course used when you suddenly become more breathless, produce more sputum, or feel unwell with a chest infection.

In bronchiectasis, the airways become widened and more prone to mucus build-up. Mucus can trap bacteria. This can lead to repeated infections, more inflammation, more coughing, and further airway irritation. Doctors sometimes call this the “vicious cycle” of bronchiectasis.

The aim of long-term antibiotics is to break this cycle. They may reduce the number of chest infections, increase the time between flare-ups, reduce bacterial load in the sputum, and improve day-to-day symptoms for some people.

Importantly, antibiotics do not cure bronchiectasis. Their use also do not replace airway clearance, exercise, vaccination, or treatment of underlying causes.

Guidelines generally consider long-term antibiotics for people who have frequent exacerbations, often three or more per year, especially when these need repeated antibiotic courses or hospital care.

The British Thoracic Society advises considering long-term antibiotics in people with bronchiectasis who have three or more exacerbations per year.

The 2025 ERS guidance now suggests considering long-term antibiotics for people at higher risk of future flare-ups. This may include those with two or more exacerbations per year, one exacerbation plus severe daily symptoms, or at least one severe exacerbation requiring hospital treatment.

Why might my specialist suggest long-term antibiotics?

Your respiratory team may suggest prophylactic antibiotics in bronchiectasis when infections keep coming back despite good basic care.
This usually means you have already worked on airway clearance, sputum testing, inhaler technique if you use inhalers, vaccination, reflux control if relevant, and treatment of asthma, COPD, immune problems, or allergic bronchopulmonary aspergillosis where present.
Long-term antibiotics may help if you:
have three or more flare-ups a year;
need repeated rescue antibiotics;
grow the same bacteria repeatedly in sputum;
have chronic Pseudomonas aeruginosa infection;
feel unwell between infections;
have flare-ups that take a long time to recover from;
or have a higher risk of severe infection.
Guidelines also note that the threshold may be lower for some people, such as those who remain very symptomatic between infections or those at higher risk of severe exacerbations.

Oral versus nebulised antibiotics: what is the difference?

Oral antibiotics are tablets or capsules. They work throughout the body. They are simple to take and suit many people.

Nebulised antibiotics are breathed into the lungs through a nebuliser. The aim is to deliver a high antibiotic dose directly into the airways, with less exposure to the rest of the body. This can be useful when bacteria live persistently in the lungs, especially Pseudomonas aeruginosa.

The choice depends on several things. These include your sputum results, your infection pattern, allergies, kidney function, hearing or balance problems, heart rhythm risk, other medicines, and how well you can manage a nebuliser.

Neither option is “better” for everyone. The best choice is the one that targets the bacteria most likely to be causing trouble, reduces flare-ups, and fits safely into your daily life.

Guideline recommendations in simple terms

For people with chronic Pseudomonas aeruginosa infection, UK guidance recommends inhaled colistin as a first option and inhaled gentamicin as a second-line alternative. It also suggests azithromycin or erythromycin if inhaled antibiotics are not tolerated or suitable, and sometimes as add-on treatment when exacerbations remain frequent.
For people without chronic Pseudomonas aeruginosa infection, UK guidance recommends azithromycin or erythromycin first. It suggests inhaled gentamicin as a second-line alternative and doxycycline if macrolides are not tolerated or do not work.
European guidance also supports long-term antibiotics for adults with bronchiectasis and three or more exacerbations per year. It suggests inhaled antibiotics for chronic Pseudomonas infection and macrolides such as azithromycin or erythromycin for many people without Pseudomonas.
More recent European guidance has strengthened support for long-term macrolides in patients at high risk of exacerbations and for inhaled antibiotics in chronic Pseudomonas infection.

Azithromycin in bronchiectasis

Azithromycin is one of the most common oral choices for prophylactic antibiotics in bronchiectasis. It belongs to a group called macrolides.

It can help in two ways. First, it acts against some bacteria. Second, it has anti-inflammatory effects in the airways. This is one reason it may reduce flare-ups even when it is not directly “killing” every organism found in sputum.

Common long-term bronchiectasis regimens include azithromycin 250 mg three times a week, 500 mg three times a week, or 250 mg daily. The British Thoracic Society notes that 250 mg three times a week can be a practical starting dose to reduce side effects, with adjustment based on response.

Before starting azithromycin, your team will usually check a sputum sample, including testing for non-tuberculous mycobacteria, often shortened to NTM. This matters because macrolides should not be used alone if active NTM infection is present. Using a macrolide on its own in that situation can make NTM harder to treat later. BTS guidance says macrolide monotherapy should be avoided if NTM is identified.
Your team may also arrange an ECG to check the heart rhythm, plus liver blood tests. They may ask about hearing or balance problems. This is routine safety care, not a reason to panic.

Possible side effects include nausea, loose stools, tummy discomfort, changes in taste, hearing or balance symptoms, liver test changes, heart rhythm effects in susceptible people, and antibiotic resistance. Many people tolerate azithromycin well, especially at lower intermittent doses.

Doxycycline, co-trimoxazole and other oral options

Doxycycline is not usually the first-choice long-term antibiotic for bronchiectasis, but it can help some people. UK guidance lists doxycycline as an alternative when macrolides are not tolerated or ineffective in non-Pseudomonas bronchiectasis.

Doxycycline can cause indigestion, sun sensitivity, and irritation of the food pipe. Taking it with plenty of water and staying upright afterwards can reduce this risk. It is not suitable in pregnancy.

Co-trimoxazole may be used in selected cases, especially when sputum cultures show bacteria that are sensitive to it and other options are unsuitable. It is not usually the headline guideline choice for long-term bronchiectasis prevention, but specialists may use it in a culture-guided way. It can interact with other medicines and may need blood monitoring in some patients.

Other oral antibiotics may occasionally be chosen. The decision should follow sputum culture results, previous response, allergies, tolerance, and local antimicrobial guidance.

A key point: your specialist will usually keep you on the same long-term oral antibiotic rather than rotate it every month. BTS guidance recommends this approach for long-term prophylactic oral antibiotics. If the antibiotic stops working, your specialist can change it based on your sputum sensitivity results.

Nebulised colomycin, colistin, tobramycin and gentamicin

Nebulised colomycin is a brand name for colistimethate sodium, often called colistin. It is commonly used for chronic Pseudomonas aeruginosa infection in bronchiectasis.

Nebulised antibiotics may suit people who repeatedly grow Pseudomonas in sputum and have frequent infections. They deliver treatment straight to the airways. This can reduce bacterial load and may reduce exacerbations.

A 2024 systematic review of 20 studies involving 3,468 adults found that inhaled antibiotics reduced the number of people having exacerbations, slightly reduced exacerbation frequency, probably reduced severe exacerbations, and slightly improved symptoms and quality of life. However, It also found that antibiotic-resistant organisms increased with treatment.

Nebulised colistin can cause cough, wheeze, chest tightness, or throat irritation. For this reason, many clinics perform a supervised test dose or challenge test when you are stable before starting inhaled antibiotics. BTS guidance recommends a suitable challenge test before starting inhaled antibiotics.

Tobramycin and gentamicin are aminoglycoside antibiotics. They may be used by nebuliser in selected patients, depending on local practice and sputum results. They can be effective against Pseudomonas, but they need caution in people with kidney problems, hearing loss, balance problems, or those taking other kidney-affecting medicines. BTS guidance advises avoiding long-term inhaled aminoglycosides when creatinine clearance is below 30 mL/min and using caution in significant hearing or balance problems.

Advantages of prophylactic antibiotics in bronchiectasis

The main advantage is fewer flare-ups. That can mean fewer rescue antibiotic courses, fewer days in bed, fewer hospital visits, and more confidence in daily life.

Some people also notice less sputum, less sputum colour change, reduced cough, and improved energy. Benefits vary. Some patients feel a clear improvement. Others gain little and stop after review.

Long-term treatment should have a clear goal. For example: “reduce exacerbations from five per year to two”, “avoid hospital admission”, or “improve daily sputum and breathlessness”. This makes review easier.

Disadvantages and risks

The main concern is antibiotic resistance. This means bacteria may become less sensitive to antibiotics over time. Resistance does not always mean the treatment has failed, but it can reduce future options.

Other disadvantages depend on the drug. Oral antibiotics can cause stomach upset, diarrhoea, thrush, rashes, liver test changes, and interactions with other medicines. Macrolides can affect heart rhythm in some people and may affect hearing or balance. Nebulised antibiotics can cause cough, wheeze, or chest tightness and take time to prepare and clean.

These risks sound worrying, but clinics reduce them with careful selection, sputum testing, ECGs, blood tests, supervised nebuliser trials, dose adjustment, and regular review.

What monitoring should patients expect?

Before starting treatment, your team may ask for:

• recent sputum culture results;
• NTM sputum testing before starting macrolides;
• ECG before starting azithromycin;
• liver function blood tests;
• kidney function tests before aminoglycosides pr co-trimoxazole;
• hearing, tinnitus or balance history;
• and a supervised nebuliser test dose for inhaled antibiotics.

After starting, you may have repeat blood tests, sputum checks, and a review at around six months and 12 months. BTS macrolide guidance recommends checking liver function one month after starting and then every six months, with an ECG one month after starting to look for new QT prolongation.

Treatment should stop if it does not help. It may also pause during certain periods if your specialist thinks a break could reduce resistance risk without increasing exacerbation risk (e.g during the Summer months). You should seek medical advice if stopping or restart long-term antibiotics.

What can you do alongside antibiotics?

Antibiotics work best as part of a full bronchiectasis plan that is adviced by your specialist.

Airway clearance remains central. A respiratory physiotherapist can teach techniques that suit your lungs and lifestyle.

Stay active where possible. Keep vaccinations up to date. Send sputum samples when your symptoms change. Drink enough fluid unless you have been told to restrict fluids. Avoid smoking and ask for help to stop if needed.

Keep a simple flare-up diary. Record dates, symptoms, sputum colour, antibiotics used, and recovery time. This helps your specialist judge whether prophylactic antibiotics are working.

Conclusion

Prophylactic antibiotics in bronchiectasis can make a real difference for the right person. They are usually considered when flare-ups happen often, especially when sputum cultures show persistent bacteria such as Pseudomonas aeruginosa. They can sometimes also be used to help reduce phlegm volume.
Oral options such as azithromycin are convenient and have strong evidence for reducing exacerbations. Doxycycline and co-trimoxazole may help selected patients when guided by culture results and tolerance. Nebulised options such as colomycin, tobramycin, and gentamicin can target bacteria directly in the lungs, especially chronic Pseudomonas.
The safest approach is personal and tailored to your needs. Your specialist will balance benefit, side effects, resistance, sputum results, and your preferences. The goal is not to frighten you with risks. The goal is to help you have fewer infections and better control, with sensible monitoring.

Frequently asked questions

1. Who needs prophylactic antibiotics in bronchiectasis?

Your specialist may consider prophylactic antibiotics if you have frequent flare-ups, often three or more per year, despite good airway clearance and standard care.Some people may qualify sooner if infections are severe or recovery is poor.

2. Is azithromycin safe long term?

Azithromycin can be safe and effective for many people, but it needs checks. Your team may arrange sputum testing for NTM, an ECG, liver blood tests, and follow-up reviews.

3. Why should macrolides be avoided if NTM is present?

Macrolides are key drugs for treating NTM. Taking a macrolide alone when active NTM is present can encourage resistance and make future NTM treatment harder.

4. Are nebulised antibiotics stronger than tablets?

Not exactly. They are different. Nebulised antibiotics deliver high levels directly to the lungs, which helps in chronic airway infection, especially Pseudomonas. Tablets may suit other infection patterns better.

5. Will I need prophylactic antibiotics forever?

Not always. Your specialist should review whether they reduce flare-ups and improve your quality of life. If they do not help, or if side effects outweigh benefits, treatment may change or stop.

For an assessment of your diagnosis and treatment.

Disclaimer: The information provided in this article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment, and is not an advertisement for medical products. Always seek the advice of your healthcare provider with any questions you may have regarding a medical condition or treatment. Your healthcare professional can assess your individual circumstances. All clinical decisions should follow an individual assessment and shared decision-making